Skip to main content
Eligibility
for females ages 35–50
Location
at San Francisco, California
Dates
study started
Principal Investigator

Description

Summary

PROSper is a prospective cohort study of 100 women 35-50 years of age with BRCA 1/2 mutations who have elected to either undergo risk reducing salpingo-oophorectomy (RRSO) or nonsurgical management. The investigators will compare the change in cardiovascular health, bone health, sexual function, quality of life, and menopausal symptoms over 3 years of follow-up between women who undergo RRSO (baseline just prior to surgery) and age-matched controls that do not undergo RRSO. The investigators hypothesis is that women who undergo a premature surgical menopause induced by RRSO have worse cardiovascular health and bone health compared with women who do not undergo RRSO.

Keywords

BRCA1 Gene Mutation BRCA2 Gene Mutation

Eligibility

You can join if…

Open to females ages 35–50

  • BRCA mutation 1/2 or "Variant suspected deleterious" mutation.
  • Female
  • Age 35-50 years
  • Able to undergo RRSO
  • Speaks English
  • Able to give informed consent

You CAN'T join if...

  • Prior history of bilateral oophorectomy
  • BRCA 1/2 deleterious mutation
  • Plans to move out of geographic region in next 3 years
  • Unable to travel to study visits

Location

Details

Status
in progress, not accepting new patients
Start Date
Sponsor
University of California, San Francisco
ID
NCT01948609
Lead Scientist
Vanessa Jacoby
Study Type
Observational
Last Updated
January 1, 2017